Filter
194
Filtered Results: 194
Text search:
buruli
ulcer
Featured
Recommendations
23
New Publications
31
Language
Document type
No document type
66
Studies & Reports
46
Guidelines
25
Strategic & Response Plan
14
Manuals
11
Brochures
7
Videos
7
Fact sheets
6
Resource Platforms
5
Training Material
3
Infographics
3
Online Courses
1
Countries / Regions
Global
20
Benin
11
Ghana
6
Liberia
6
Togo
5
Nigeria
4
Congo, Democratic Republic of
4
Africa
3
Sierra Leone
2
Syria
2
Iran
2
Jordan
2
Germany
2
Saudi Arabia
2
Western and Central Europe
2
Lebanon
2
Sudan
2
Iraq
2
Pakistan
2
Kenya
1
Cameroon
1
Albania
1
Burkina Faso
1
Afghanistan
1
Malawi
1
Morocco
1
Qatar
1
Middle East and North Africa
1
Tunisia
1
Uganda
1
Djibouti
1
Egypt
1
Yemen
1
Greece
1
Palestine
1
Georgia
1
Libya
1
Somalia
1
Ecuador
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
49
Countries
46
Public Health
11
Capacity Building
6
Pharmacy & Technologies
5
Key Resources
3
Women & Child Health
1
Toolboxes
NTDs
96
TB
11
Rapid Response
6
Caregiver
3
Ebola
2
Planetary Health
2
NCDs
2
Global Health Education
2
Refugee
1
Natural Hazards
1
HIV
1
Disability
1
COVID-19
1
Pharmacy
1
AMR
1
A guide for field health workers
Buruli Ulcer Prevention of Disability (POD)
recommended
This manual is for use by doctors, nurses, rehabilitation specialists, National Buruli ulcer Control Programme managers and other health workers involved in the prevention of disability activities in Buruli ulcer.
Guidance for health workers
Laboratory diagnosis of Buruli ulcer
recommended
A manual for health care providers.
This manual provides expert guidance on the laboratory techniques and procedures used in the diagnosis of Buruli ulcer, a disease caused by Mycobacterium ulcerans. Aimed at laboratory technicians and scientists working on this disease, the manual details the exac...
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection....
Buruli ulcer [comic]
recommended
Buruli ulcer mostly affects children. This comic is aimed at giving them a better knowledge of the disease.
A total of 18 laboratories from 13 countries participated in the four rounds of EQA: 10 laboratories from eight African endemic countries, four of which participated in all four rounds and three in three rounds. The overall results showed that the median performance of these laboratories improved ov...
In 2009, WHO’s Second International Conference on Buruli Ulcer Control and Research resolved to strengthen the capacity of national laboratories to confirm cases of the disease, but advised that “efforts are still needed to develop simple diagnostic tools usable in the field as well as disabilit...
This course is intended to provide basic information for front-line health workers to be able to implement the recommended control measures to minimize the negative impact of Buruli ulcer on populations.
In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified:
a diagnostic test for early detection of Buruli ulcer in symptomatic patients with sufficient positive...
The Lancet olume 395, ISSUE 10232, P1259-1267, April 18, 2020. Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifa...
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of...
The Lancet Global Health Volume 7, ISSUE 7, e912-e922, July 01, 2019
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...
Current Tropical Medicine Reports (2018) 5:247–256 https://doi.org/10.1007/s40475-018-0166-2 .Purpose of the Review Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aim...
A major objective of this open access book is to summarize the current status of Buruli Ulcer (BU) research for the first time. It will identify gaps in our knowledge, stimulate research and support control of the disease by providing insight into approaches for surveillance, diagnosis, and treatmen...
